Venaproct Alium (Suppositories) Instructions for Use

Marketing Authorization Holder

Aliym, JSC (Russia)

Manufactured By

Altpharm LLC (Russia)

Or

Binnopharm JSC (Russia)

ATC Code

B02BC (Local hemostatics)

Active Substance

Sodium alginate (Ph.Eur. European Pharmacopoeia)

Dosage Form

Venaproct Alium

Rectal suppositories 250 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories from light gray to gray in color with a possible yellowish tint, torpedo-shaped; the presence of a whitish coating on the surface of the suppository is allowed.

Excipients: hard fat (Witepsol H15).

5 pcs. – contour cell packs (2) – cardboard packs.

Clinical-Pharmacological Group

Drug with hemostatic, anti-inflammatory, and wound-healing action for topical use in proctology

Pharmacotherapeutic Group

Hemostatic agents; vitamin K and other hemostatic agents; topical hemostatic agents

Pharmacological Action

A hemostatic drug for topical use. It is a natural polysaccharide obtained from brown seaweed. It has a pronounced hemostatic effect and possesses anti-inflammatory and reparative properties.

Indications

• Anal fissures in the epithelialization stage.
• Chronic bleeding hemorrhoids.
• Proctosigmoiditis.
• Inflammation of the rectum in the postoperative period.

ICD codes

Dosage Regimen

Administer one suppository rectally twice daily, typically in the morning and evening.

The standard treatment duration is 7 to 14 days, which should be adjusted based on the severity of the disease and the clinical response observed.

Adverse Reactions

Adverse reactions are infrequent and typically mild.

Allergic reactions, including localized skin reactions such as itching or rash, are possible. Discontinue use immediately if any signs of hypersensitivity appear.

Contraindications

• Hypersensitivity to sodium alginate or any of the excipients in the suppository formulation.

Drug Interactions

No specific drug interactions with sodium alginate for rectal administration have been reported to date.

Given its local mechanism of action and minimal systemic absorption, the potential for clinically significant interactions is considered low.

Overdose

Overdose is unlikely due to the topical route of administration and the characteristics of the suppository dosage form.

No specific symptoms of overdose have been reported. In case of suspected excessive use, discontinue treatment and manage any presenting symptoms supportively.

Use in Pregnancy and Lactation

Rectal use during pregnancy and lactation is possible according to indications.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.